Table 3.
Meta‐Analyzed HRs and 95% CIs of Incident Dementia in OAC Comparison Cohorts: MarketScan and Optum, 2010–2015
| Variable | Warfarin | Dabigatran | Warfarin | Rivaroxaban | Warfarin | Apixaban |
|---|---|---|---|---|---|---|
| N | 46 483 | 46 483 | 61 641 | 61 641 | 31 089 | 31 089 |
| Dementia, N | 739 | 724 | 944 | 648 | 474 | 277 |
| Follow‐up, mean, y | 1.7 | 1.9 | 1.4 | 1.2 | 1.2 | 0.8 |
| Incidence rate (per 1000 person‐years) | 9.2 | 8.0 | 10.5 | 8.7 | 12.9 | 11.0 |
| HRs (95% CIs) | ||||||
| Model 1a | 1 | 0.85 (0.74–0.97) | 1 | 0.85 (0.77–0.94) | 1 | 0.80 (0.63–1.03) |
| Model 2b | 1 | 0.85 (0.71–1.01) | 1 | 0.85 (0.76–0.94) | 1 | 0.80 (0.65–0.97) |
| Rivaroxaban | Dabigatran | Apixaban | Dabigatran | Rivaroxaban | Apixaban | |
|---|---|---|---|---|---|---|
| N | 28 235 | 28 235 | 11 882 | 11 882 | 31 143 | 31 143 |
| Dementia, N | 290 | 399 | 87 | 119 | 360 | 279 |
| Follow‐up, mean, y | 1.2 | 1.7 | 0.8 | 1.3 | 1.1 | 0.8 |
| Incidence rate (per 1000 person‐years) | 8.5 | 8.2 | 8.8 | 7.3 | 10.6 | 11.0 |
| HRs (95% CIs) | ||||||
| Model 1a | 1 | 1.03 (0.85–1.24) | 1 | 0.95 (0.65–1.38) | 1 | 0.99 (0.85–1.16) |
| Model 2b | 1 | 1.02 (0.79–1.32) | 1 | 0.92 (0.63–1.36) | 1 | 1.01 (0.86–1.19) |
CI indicates confidence interval; HR, hazard ratio; OAC, oral anticoagulant.
a
Model 1 was adjusted for age, sex, and prevalent cognitive impairment in the study from MarketScan and for age, sex, race, education level, household income level, and prevalent cognitive impairment in the study from Optum.
b
Model 2 was additionally adjusted for comorbidities, medications, and CHA2DS2‐VASc and HAS‐BLED scores.